NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Sierra Oncology LLC - a GSK company
Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia
Interventions: Momelotinib
Countries: United States, Australia, Canada, France, Germany
This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved stable disease or better with momelotinib treatment while enrolled in a previous clinical trial.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Key Inclusion Criteria: * Currently enrolled in study CCL09101E, or YM387-II-02, or successfully completed 24 weeks of study GS-US-352-1672 * Able to comprehend and willing to sign informed consent form Key Exclusion Criteria: * Known hypersensitivity to momelotinib, its metabolites, or formulation excipients Note: Other protocol defined Inclusion/Exclusion criteria may apply.
- Scottsdale, Arizona, United States
- Orange, California, United States
- Stanford, California, United States
- Whittier, California, United States
- Jacksonville, Florida, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Ann Arbor, Michigan, United States
- Rochester, Minnesota, United States
- St Louis, Missouri, United States
- New York, New York, United States
- The Bronx, New York, United States
- Cleveland, Ohio, United States
- Houston, Texas, United States
- Salt Lake City, Utah, United States
- Frankston, Victoria, Australia
- Parkville, Victoria, Australia
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
- La Tronche, France
- Paris, France
- Minden, Germany